Mesoblast (MESO) news

Mesoblast Limited - Anticipate that we may continue to incur significant losses for foreseeable future

MesoBlast Ltd FY revenue USD 120.3 million

Mesoblast Ltd. reported fiscal year (FY) revenue of USD 120.3 million, reflecting the company’s financial performance during the period. The revenue figure provides insight into the company’s operations and market position, though specific details regarding revenue composition or growth drivers…

Mesoblast Ryoncil net revenue $36M for 4Q

Mesoblast Limited (Nasdaq: MESO; ASX: MSB) reported net revenue of US$36 million for Ryoncil® in the fourth quarter ended June 30, 2026. This marked a strong performance for the flagship product, which achieved total net revenue of US$115 million for the first full year following its FDA approval.…

Mesoblast: Looking to extend FDA-approved label for Ryoncil

Mesoblast, Inc. is currently exploring opportunities to expand the FDA-approved label for its cell therapy product RYONCIL (remestemcel-L-rknd). The therapy, approved in December 2024, is currently indicated for steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients…

Mesoblast: had US$103M of cash at June 30

Mesoblast Limited (ASX: MSB; Nasdaq: MESO) reported a cash balance of US$103 million as of June 30, 2026, according to its financial records. This figure reflects the company’s ongoing efforts to manage liquidity and extend its operational runway to support key development milestones across its…